Evogene Stock Analysis

EVGN Stock  USD 1.67  0.05  3.09%   
Evogene is undervalued with Real Value of 2.14 and Target Price of 3.62. The main objective of Evogene stock analysis is to determine its intrinsic value, which is an estimate of what Evogene is worth, separate from its market price. There are two main types of Evogene's stock analysis: fundamental analysis and technical analysis.
The Evogene stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Evogene is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Evogene Stock trading window is adjusted to America/New York timezone.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.

Evogene Stock Analysis Notes

The book value of the company was currently reported as 2.38. The company recorded a loss per share of 4.46. Evogene had not issued any dividends in recent years. The entity had 1:10 split on the 25th of July 2024. Evogene Ltd., together with its subsidiaries, operates as a computational biology company. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel. Evogene operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 133 people. To learn more about Evogene call Ofer CPA at 972 8 931 1900 or check out https://www.evogene.com.

Evogene Quarterly Total Revenue

914,000

Evogene Investment Alerts

Evogene generated a negative expected return over the last 90 days
Evogene has high historical volatility and very poor performance
Evogene may become a speculative penny stock
Evogene has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 5.64 M. Net Loss for the year was (25.95 M) with profit before overhead, payroll, taxes, and interest of 766 K.
Evogene currently holds about 35.25 M in cash with (21.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.86.
Evogene has a frail financial position based on the latest SEC disclosures
Latest headline from news.google.com: Evogene price target lowered to 5 from 12 at Lake Street - TipRanks

Evogene Upcoming and Recent Events

Earnings reports are used by Evogene to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
14th of March 2024
Upcoming Quarterly Report
View
16th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Evogene Largest EPS Surprises

Earnings surprises can significantly impact Evogene's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-05-23
2024-03-31-0.09-0.080.0111 
2022-03-10
2021-12-31-0.2-0.180.0210 
2021-11-17
2021-09-30-0.17-0.19-0.0211 
View All Earnings Estimates

Evogene Thematic Classifications

In addition to having Evogene stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Chemicals Idea
Chemicals
USA Equities from Chemicals industry as classified by Fama & French

Evogene Stock Institutional Investors

Shares
Armistice Capital, Llc2024-09-30
194.7 K
Renaissance Investment Group, Llc2024-09-30
10 K
Pnc Financial Services Group Inc2024-09-30
3.8 K
Group One Trading, Lp2024-06-30
0.0
Bnp Paribas Arbitrage, Sa2024-06-30
0.0
Commonwealth Equity Services Inc2024-06-30
0.0
Malaga Cove Capital, Llc2024-06-30
0.0
Virtu Financial Llc2024-06-30
0.0
Note, although Evogene's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Evogene Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.96 M.

Evogene Profitablity

The company has Profit Margin (PM) of (2.1) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (6.67) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $6.67.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.63)(0.66)
Return On Capital Employed(0.60)(0.63)
Return On Assets(0.47)(0.49)
Return On Equity(1.98)(1.88)

Management Efficiency

Evogene has return on total asset (ROA) of (0.2846) % which means that it has lost $0.2846 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8237) %, meaning that it created substantial loss on money invested by shareholders. Evogene's management efficiency ratios could be used to measure how well Evogene manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -0.66. In addition to that, Return On Capital Employed is likely to drop to -0.63. At this time, Evogene's Total Assets are very stable compared to the past year. As of the 26th of November 2024, Non Currrent Assets Other is likely to grow to about 28.4 K, while Other Assets are likely to drop 0.95.
Last ReportedProjected for Next Year
Book Value Per Share 0.63  0.60 
Tangible Book Value Per Share 0.34  0.32 
Enterprise Value Over EBITDA(15.80)(16.59)
Price Book Value Ratio 31.26  29.70 
Enterprise Value Multiple(15.80)(16.59)
Price Fair Value 31.26  29.70 
Enterprise Value367.6 M349.2 M
At Evogene, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Operating Margin
(6.67)
Profit Margin
(2.10)
Beta
1.084
Return On Assets
(0.28)
Return On Equity
(0.82)

Technical Drivers

As of the 26th of November, Evogene shows the Standard Deviation of 5.17, mean deviation of 3.72, and Variance of 26.77. Evogene technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.

Evogene Price Movement Analysis

Execute Study
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Evogene middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Evogene. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Evogene Outstanding Bonds

Evogene issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Evogene uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Evogene bonds can be classified according to their maturity, which is the date when Evogene has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Evogene Predictive Daily Indicators

Evogene intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Evogene stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Evogene Forecast Models

Evogene's time-series forecasting models are one of many Evogene's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Evogene's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Evogene Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Evogene prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Evogene shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Evogene. By using and applying Evogene Stock analysis, traders can create a robust methodology for identifying Evogene entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(4.61)(4.84)
Operating Profit Margin(4.70)(4.94)
Net Loss(4.23)(4.45)
Gross Profit Margin 0.70  0.74 

Current Evogene Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Evogene analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Evogene analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
3.62Strong Buy2Odds
Evogene current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Evogene analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Evogene stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Evogene, talking to its executives and customers, or listening to Evogene conference calls.
Evogene Analyst Advice Details

Evogene Stock Analysis Indicators

Evogene stock analysis indicators help investors evaluate how Evogene stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Evogene shares will generate the highest return on investment. By understating and applying Evogene stock analysis, traders can identify Evogene position entry and exit signals to maximize returns.
Begin Period Cash Flow29 M
Long Term Debt10.4 M
Common Stock Shares Outstanding4.6 M
Total Stockholder Equity12.1 M
Tax Provision16 K
Property Plant And Equipment Net3.4 M
Cash And Short Term Investments31.1 M
Cash20.8 M
Accounts Payable1.8 M
Net Debt-9.3 M
50 Day M A2.372
Total Current Liabilities6.9 M
Other Operating Expenses32 M
Non Current Assets Total16.6 M
Non Currrent Assets Other28 K
Stock Based Compensation1.9 M
When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evogene. If investors know Evogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.46)
Revenue Per Share
1.881
Quarterly Revenue Growth
0.398
Return On Assets
(0.28)
Return On Equity
(0.82)
The market value of Evogene is measured differently than its book value, which is the value of Evogene that is recorded on the company's balance sheet. Investors also form their own opinion of Evogene's value that differs from its market value or its book value, called intrinsic value, which is Evogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evogene's market value can be influenced by many factors that don't directly affect Evogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.